With targeted drugs, chronic myelogenous leukemia therapy may follow HIV's model.
Tuma
Rabiya S
RS
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000191:economics* / Q000494:pharmacology*; D023241:Antiretroviral Therapy, Highly Active / Q000191:economics; D001549:Benzamides; D000069439:Dasatinib; D004334:Drug Administration Schedule; D016527:Drug Costs; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D007532:Isoleucine; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000191:economics / Q000235:genetics; D009154:Mutation; D010879:Piperazines / Q000191:economics / Q000494:pharmacology; D047428:Protein Kinase Inhibitors / Q000191:economics / Q000494:pharmacology; D011743:Pyrimidines / Q000191:economics / Q000494:pharmacology; D013844:Thiazoles / Q000191:economics / Q000494:pharmacology; D013912:Threonine; D014481:United States; D003521:Cyclopropanes; D011720:Pyrazoles
D000970:Antineoplastic Agents; D001549:Benzamides; D000069439:Dasatinib; D016044:Fusion Proteins, bcr-abl; D000068877:Imatinib Mesylate; D007532:Isoleucine; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D013912:Threonine; C484810:tozasertib; D003521:Cyclopropanes; D011720:Pyrazoles